Clinical trialPhase 2Terminated
ZN-c3 + Gemcitabine in Pancreatic Cancer
Phase 2 Single Arm Trial Testing the ZN-c3 WEE1 Inhibitor in Combination With Gemcitabine in Second-Line Advanced Pancreatic Adenocarcinoma
- Outcome
- Stopped earlyStudy stopped early due to reaching the minimum number of DLTs required for halting the study due to toxicity. (Toxicity)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 16 November 2023
- Expected end
- 23 May 2026
- Enrollment
- 12 participants
- Sites
- 1
- Primary outcomes
- 6-month Progression-Free Survival (PFS) Rate
- Sponsor
- Other
- Results posted
- 2026-10-27
- Last update
- 27 October 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study is being done to test the safety and effectiveness of combining ZN-c3 and Gemcitabine in participants with pancreatic cancer. The names of the study drugs involved in this study are: * ZN-c3 (a small molecule inhibitor of the WEE1 tyrosine kinase) * Gemcitabine (a nucleoside metabolic inhibitor)
Detailed description public domain (ClinicalTrials.gov)
This is an open label, single arm phase 2 trial evaluating ZN-c3 combined with gemcitabine in second-line advanced pancreatic cancer. There are lab experiments that show that pancreatic cancer cells can respond to a combination of ZN-c3, an experimental drug, with gemcitabine. The U.S. Food and Drug Administration (FDA) has not approved ZN-c3 as a treatment for any disease. The FDA has approved gemcitabine as a treatment option for advanced pancreatic cancer. The research study procedures include screening for eligibility, study treatment including evaluations and follow up visits, radiological scans (Computerized Tomography, Magnetic Resonance Imaging, or Positron Emission Tomography), blood tests, electrocardiogram, and tumor biopsy. It is expected that about 34 people will take part in this research study. The Lustgarten Foundation for Pancreatic Research and Stand Up to Cancer are supporting this research study by providing funding to conduct the study. Zentalis is supplying the study drug, ZN-c3.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
6-month Progression-Free Survival (PFS) Rate [6 months]. Number, percent of participants (95% Confidence Interval). All Study Participants (n=12): 16.7 (4.7 to 59.1).